Hypoxic cell chemosensitization

Hypoxic cell chemosensitization" is **not a specific molecule or receptor**, but rather describes a therapeutic strategy aimed at overcoming the resistance of hypoxic tumor cells to chemotherapy. Hypoxia—low oxygen conditions—is common in solid tumors and leads to treatment resistance, largely mediated by cellular adaptations such as upregulation of hypoxia-inducible factors (HIFs)[5][1]. These adaptations make cancer cells less susceptible to conventional therapies. To address this challenge, researchers have developed **hypoxia-targeted therapies** such as **hypoxia-activated prodrugs** (HAPs). These drugs remain inactive under normal oxygen levels but are converted into cytotoxic agents specifically within the low oxygen environment of tumors. Examples include tirapazamine, AQ4N (banoxantrone), PR‑104, EO9 (apaziquone), TH‑302 (evofosfamide), and SN30000[3]. The goal is to selectively kill chemoresistant hypoxic tumor cells while sparing healthy tissue. Because "Hypoxic cell chemosensitization" refers to a process or therapeutic approach—not an individual molecular target—it does not fit standard target classification schemes used for receptors, enzymes, or other drug targets. Therefore: > There is something incorrect with this entry as a "target": it does not refer to a single protein/gene/receptor/enzyme/transporter but rather an effect or strategy involving multiple pathways and molecules. Key points supported by search results: *Hypoxia in tumors drives chemoresistance through HIF-mediated mechanisms and other adaptive responses[1][5].* *Therapeutic strategies include using HAPs that are activated only under low oxygen conditions found in tumors[3].* *This approach aims at improving the effectiveness of chemotherapy against resistant cancer cell populations.* In summary: "Hypoxic cell chemosensitization" should not be considered a canonical molecular target; it represents an important concept/strategy in oncology drug development focused on reversing therapy resistance due to tumor hypoxia.

Other names

Hypoxic cell chemosensitizationChemosensitization of hypoxic cellsHypoxia-induced chemoresistance reversal

Selective activation of prodrugs under hypoxic conditions to kill resistant tumor cells[3]